Loading...
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study.
Hickish, T Andre, T Wyrwicz, L Saunders, Mark P Sarosiek, T Kocsis, J Nemecek, R Rogowski, W Lesniewski-Kmak, K Petruzelka, L
Hickish, T
Andre, T
Wyrwicz, L
Saunders, Mark P
Sarosiek, T
Kocsis, J
Nemecek, R
Rogowski, W
Lesniewski-Kmak, K
Petruzelka, L
Citations
Altmetric:
Abstract
MABp1, an antibody that targets interleukin 1α, has been associated with antitumour activity and relief of debilitating symptoms in patients with advanced colorectal cancer. We sought to establish the effect of MABp1 with a new primary endpoint in patients with advanced colorectal cancer.
Description
Date
2017-02
Publisher
Collections
Keywords
Type
Article
Citation
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. 2017, 18(2):192-201 Lancet Oncol